Clinicopathological characteristics among 83 patients with different mutation status
| Features | n | BRCA+ (n = 20, %) | non-BRCA+ (n = 25, %) | Negative (n = 38, %) | P1-value* | P2-value* |
|---|---|---|---|---|---|---|
| Age of onset | ||||||
| Mean ± size | 45.7 ± 9.6 | 53.8 ± 10.7 | 51.9 ± 8.7 | 0.015a | 0.432a | |
| ≤ 45 | 23 | 11 (55.0%) | 3 (12.0%) | 9 (23.7%) | 0.023 | 0.334 |
| > 45 | 60 | 9 (45.0%) | 22 (88.0%) | 29 (76.3%) | ||
| Axillary lymph node metastasis | 0.005 | 1.000 | ||||
| Yes | 33 | 14 (70.0%) | 8 (32.0%) | 11 (28.9%) | ||
| No | 50 | 6 (30.0%) | 17 (68.0%) | 27 (71.1%) | ||
| TNM stage | 0.011b | 0.273b | ||||
| 0 + I | 37 | 4 (20.0%) | 10 (40.0%) | 23 (60.5%) | ||
| II | 27 | 9 (45.0%) | 10 (40.0%) | 8 (21.1%) | ||
| III | 19 | 7 (35.0%) | 5 (20.0%) | 7 (18.4%) | ||
| Tumor grade | 0.223b | 0.986b | ||||
| I | 14 | 1 (5.0%) | 5 (20.0%) | 8 (21.1%) | ||
| II | 54 | 16 (80.0%) | 15 (60.0%) | 23 (60.5%) | ||
| III | 15 | 3 (15.0%) | 5 (20.0%) | 7 (18.4%) | ||
| Luminal type | 0.002b | 0.293b | ||||
| Luminal A | 4 | 2 (10.0%) | 4 (16.0%) | 14 (36.8%) | ||
| Luminal B | 21 | 8 (40.0%) | 15 (60.0%) | 17 (44.7%) | ||
| HER2 overexpressing | 11 | 2 (10.0%) | 5 (20.0%) | 4 (10.5%) | ||
| Triple negative | 12 | 8 (40.0%) | 1 (4.0%) | 3 (7.9%) | ||
*Fisher’s precise test. aStudent’s t-test; brank-sum test; P1-value: BRCA+ group vs. the negative group; P2-value: non-BRCA+ group vs. the negative group.